Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis.

Objectives: To assess the beneficial and harmful effects of adding ivabradine to usual care in participants with heart failure.

Design: A systematic review with meta-analysis and trial sequential analysis.

Eligibility Criteria: Randomised clinical trials comparing ivabradine and usual care with usual care (with or without) placebo in participants with heart failure.

Effects of adding ivabradine to usual care in patients with angina pectoris: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Objective: To determine the impact of ivabradine on outcomes important to patients with angina pectoris caused by coronary artery disease.

Methods: We conducted a systematic review. We included randomised clinical trials comparing ivabradine versus placebo or no intervention for patients with angina pectoris due to coronary artery disease published prior to June 2020.

Coronary artery bypass surgery plus medical therapy versus medical therapy alone for ischaemic heart disease: a protocol for a systematic review with meta-analysis and trial sequential analysis.

Background: Despite increasing survival, cardiovascular disease remains the primary cause of death worldwide with an estimated 7.4 million annual deaths. The main symptom of ischaemic heart disease is chest pain (angina pectoris) most often caused by blockage of a coronary artery.

Selective serotonin reuptake inhibitors are still harmful and ineffective. Responses to the comments by Hieronymus .

In this response, we address point by point the additional issues raised by Hieronymus et al. in their second round of critique of our systematic review on selective serotonin reuptake inhibitors for major depression. We repulse that we are biased or mistaken in any major ways.

Great boast, small roast on effects of selective serotonin reuptake inhibitors: response to a critique of our systematic review.

Our systematic review in BMC Psychiatry concluded that selective serotonin reuptake inhibitors (SSRIs) compared with placebo significantly increase the risk of serious adverse events (SAEs) in patients with major depression and the potential beneficial effects of SSRIs seem to be outweighed by the harms. Hieronymus et al. accused us of methodological inaccuracies and blatant errors.